https://www.businessline.global/new-phase-3-data-show-tak-620-maribavir-an-investigational-drug-for-the-treatment-of-transplant-recipients-with-refractory-resistant-cytomegalovirus-cmv-infections-meets-primary-endpoint/press-release/